Table 5.
Predictors of post-operative survival after neurosurgical treatment of metastatic CNS disease
| Cranial Procedures | Spinal Procedures | |||
|---|---|---|---|---|
| Univariate Hazards Ratio (95%CI) | Multivariate Hazards Ratio (95%CI) | Univariate Hazards Ratio (95%CI) | Multivariate Hazards Ratio (95%CI) | |
| Age at time of surgery (per year increase) | 1.03 (1.01–1.05) | 1.04 (1.02–1.07) | 0.99 (0.98–1.01) | - |
| Time from diagnosis of breast cancer to surgery (per year) | 0.96 (0.93–0.98) | 0.97 (0.94–0.99) | 0.98 (0.96–1.00) | 0.97 (0.95–0.99) |
| White Race (vs non-white) | 0.67 (0.44–1.01) | NS | 0.73 (0.50–1.07) | - |
| Rural location vs non-rural | 1.15 (0.72–1.85) | - | 1.14 (0.74–1.78) | - |
| Married (vs non-married) | 1.07 (0.83–1.38) | - | 0.92 (0.75–1.14) | - |
| Charlson comorbidity score (per unit increase) | 1.18 (1.10–1.27) | 1.17 (1.09–1.25) | 1.05 (0.97–1.14) | - |
| Admission to hospital through ER | 1.30 (0.97–1.75) | NS | 1.41 (1.10–1.79) | 1.53 (1.20–1.97) |
| Poor/Undifferentiated histology vs well/moderately differentiated | 0.91 (0.70–1.19) | - | 1.51 (1.17–1.95) | 1.49 (1.14–1.95) |
| Positive Estrogen Receptor vs Negative Estrogen Receptor | 0.79 (0.55–1.14) | NS | 0.47 (0.28–0.79) | NS |
| Unknown Estrogen Receptor vs Negative Estrogen Receptor | 0.72 (0.53–0.98) | NS | 0.61 (0.37–1.00) | NS |
| Positive Progesterone Receptor vs Negative progesterone receptor | 0.85 (0.58–1.25) | - | 0.48 (0.32–0.72) | 0.54 (0.34–0.87) |
| Unknown Progesterone receptor vs Negative Progesterone receptor | 0.77 (0.58–1.03) | - | 0.71 (0.50–1.00) | NS |
| Stage 4 disease at diagnosis of breast cancer | 1.81 (1.22–2.69) | 1.63 (1.07–2.47) | 0.99 (0.73–1.34) | - |